Adenocarcinoma of prostate Intermediate Risk | Adenocarcinoma of prostate High risk | TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
patients must have histologically confirmed intermediate or high risk prostate adenocarcinoma. intermediate risk disease comprises t2b/c tumors, gleason 7 histology, or psa 10-20. high risk tumors comprise t3-4, gleason 8 or higher histology, or psa greater than 20.
boolean
C0007112 (UMLS CUI [1,1])
C3640764 (UMLS CUI [1,2])
C0007112 (UMLS CUI [2,1])
C4319571 (UMLS CUI [2,2])
C3258246 (UMLS CUI [3])
C3203027 (UMLS CUI [4])
C0201544 (UMLS CUI [5])
Age
Item
age > 18 years.
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of greater than 5 years.
boolean
C0023671 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
patients must have normal organ and marrow function.
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
Absence Secondary malignant neoplasm of lymph node Pelvic CT of Pelvis | Absence Secondary malignant neoplasm of lymph node Pelvic MRI of Pelvis
Item
no pelvic lymph node metastases based on pelvic ct scan or mri.
boolean
C0332197 (UMLS CUI [1,1])
C0686619 (UMLS CUI [1,2])
C0030797 (UMLS CUI [1,3])
C0412628 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0686619 (UMLS CUI [2,2])
C0030797 (UMLS CUI [2,3])
C0203201 (UMLS CUI [2,4])
Secondary malignant neoplasm of bone Absent | Whole body bone scan Required
Item
no bone metastasis. a whole body bone scan is required to rule out metastatic disease.
boolean
C0153690 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3863086 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Prior radiation therapy Adenocarcinoma of prostate | Prior Chemotherapy Adenocarcinoma of prostate | Antiandrogen therapy Adenocarcinoma of prostate
Item
any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen deprivation hormonal therapy for the treatment of prostate adenocarcinoma.
boolean
C0279134 (UMLS CUI [1,1])
C0007112 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C0007112 (UMLS CUI [2,2])
C0279492 (UMLS CUI [3,1])
C0007112 (UMLS CUI [3,2])
Investigational New Drugs
Item
patients may not be receiving any other investigational agents.
boolean
C0013230 (UMLS CUI [1])
Allergic Reaction Compound Sorafenib Similar | Allergic Reaction Compound Investigational New Drugs Similar
Item
history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or other agents used in this study.
boolean
C1527304 (UMLS CUI [1,1])
C1706082 (UMLS CUI [1,2])
C1516119 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
C1527304 (UMLS CUI [2,1])
C1706082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
HIV Infection | Hepatitis B, Chronic | Hepatitis C, Chronic
Item
known human immunodeficiency virus (hiv) infection or chronic hepatitis b or c.
boolean
C0019693 (UMLS CUI [1])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
Anticoagulation Therapy | Warfarin | Heparin
Item
patients receiving anti-coagulation treatment with an agent such as warfarin or heparin will not be allowed to participate.
boolean
C0003281 (UMLS CUI [1])
C0043031 (UMLS CUI [2])
C0019134 (UMLS CUI [3])